Signing of a collaboration agreement with the Hospital Clínico de Barcelona Consortium and the Fundación Clínic for Bio-medical Research, to search for a new treatment for Leukaemia.
The collaboration agreement was signed on 26 October 2016.
Moment the agreement was signed by Mr. Joan Ros Petit (Chairman of the Bosch Aymerich Private Foundation, and Dr. Campistol (General Director of the Hospital Clínico de Barcelona Consortium)
Contribution: € 200,000
Specifically, the foundation’s contribution is part of the ARI project www.projecteari.com and will be addressed to the clinical trial with 5 patients as a preliminary step for the approval of treatment by the Spanish Agency for Medicines and Health Products (AEMPS).
This treatment is currently only available in the U.S. at a cost of more than $1 million, in addition to administrative issues, making it virtually unaffordable for most patients.
This treatment is especially effective in children and young people with a certain type of leukaemia where the degree of cure is 85% effective.
With this project in which the Foundation participates, the aim is to develop this treatment here at the Hospital Clínico, thus becoming the first centre in Europe to have the treatment available, as well as being able to apply it to patients at a much lower cost, and therefore it can benefit many people who would not otherwise have access to it.